Matinas BioPharma | Investor Presentation Deck | 31 slides · page 24 of 31
The chart shows dose-dependent inhibition; LNC formulations consistently outperform Taxol.
Pitch deck · traction · show_traction · dense density
Slide locked Sign in to view
Slide schematic 6/6
chart 1/1 list 1/1 paragraph 2/2 title 2/2
Components 6
line bullet paragraph paragraph action-title headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.